Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases

NCT06435195 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College Hospital

Phase

Observational

Started

2024-01-01

Last updated

2024-05-30

Condition(s) studied

Pituitary Diseases

Investigational drug(s) / intervention(s)

Surgical RemovalBiopsy

Surgical Removal: Resection of pituitary pathologies.

Biopsy: Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis

Study summary

The goal of this observational study is to systematically describe the clinical characteristics and outcomes of patients with pituitary complex and rare diseases at Peking Union Medical College Hospital. The main questions it aims to answer are:

* What are the influencing factors and rates of remission?
* What are the comorbidities associated with these diseases?
* What are the perioperative events, radiological findings, and pathological features?

Researchers will compare different patient groups to see if there are significant differences in these outcomes.

Participants will:

* Undergo detailed clinical evaluations.
* Provide medical history and data for analysis.
* Participate in follow-up assessments to monitor disease progression and treatment outcomes.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Diagnosed with rare sellar diseases including but not limited to pituitary adenomas (such as Thyrotropin-secreting pituitary adenomas, GH-secreting adenomas), craniopharyngiomas, Rathke's cleft cysts, sellar region germ cell tumors, cavernous sinus syndrome, and other diseases * Detailed medical history, including clinical symptoms, treatment plans and follow-up outcomes Exclusion Criteria: * Incomplete medical records, especially missing key imaging diagnostic results * Patients with coexisting primary central nervous system diseases unrelated to sellar region diseases (such as severe traumatic brain injury) * Patients whose sellar region pathological diagnosis was changed or overturned during the follow-up period

Primary outcome measure(s)

Remission — Postoperative one week and extends to the latest follow-up, estimated at up to 3 years
Hormonal normalization and free of pathologies

Trial sites (1)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	Beijing Municipality	Recruiting

More Peking Union Medical College Hospital trials in China

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors Recruiting

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) Recruiting

An Observational Cohort Study to Obese Patients With Weight Cycling Active, not recruiting

A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06435195 on ClinicalTrials.gov ↗ ← All trials in China